Ameriprise
AUPH icon

Ameriprise’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ameriprise’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$659K Buy
44,448
+33,845
+319% +$495K ﹤0.01% 3475
2025
Q4 		$169K Sell
10,603
-5
-0% -$71 ﹤0.01% 3953
2025
Q3 		$117K Sell
10,608
-123,695
-92% -$1.35M ﹤0.01% 3965
2025
Q2 		$1.14M Buy
134,303
+102,888
+328% +$825K ﹤0.01% 3211
2025
Q1 		$253K Sell
31,415
-6,381
-17% -$51.7K ﹤0.01% 3727
2024
Q4 		$339K Buy
37,796
+26,981
+249% +$220K ﹤0.01% 3678
2024
Q3 		$79.3K Buy
10,815
+130
+1% +$806 ﹤0.01% 3857
2024
Q2 		$61K Buy
+10,685
New +$56.3K ﹤0.01% 3809
2020
Q1 		– Sell
-146,841
Closed -$2.98M – 3640
2019
Q4 		$2.98M Sell
146,841
-212,250
-59% -$1.96M ﹤0.01% 2525
2019
Q3 		$1.92M Sell
359,091
-3,248
-0.9% -$19.7K ﹤0.01% 2713
2019
Q2 		$2.38M Sell
362,339
-3,171
-0.9% -$20.2K ﹤0.01% 2643
2019
Q1 		$2.38M Sell
365,510
-1,696
-0.5% -$11.3K ﹤0.01% 2661
2018
Q4 		$2.5M Sell
367,206
-2,146
-0.6% -$12.4K ﹤0.01% 2544
2018
Q3 		$2.45M Buy
369,352
+69,360
+23% +$389K ﹤0.01% 2738
2018
Q2 		$1.69M Buy
299,992
+40,138
+15% +$224K ﹤0.01% 2798
2018
Q1 		$1.35M Buy
259,854
+22,501
+9% +$120K ﹤0.01% 2845
2017
Q4 		$1.07M Buy
237,353
+25,784
+12% +$143K ﹤0.01% 2948
2017
Q3 		$1.33M Buy
211,569
+60,101
+40% +$379K ﹤0.01% 2834
2017
Q2 		$928K Buy
+151,468
New +$1.02M ﹤0.01% 2976

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise's AUPH Position: Q1 2026 in Review

Ameriprise increased its Aurinia Pharmaceuticals (AUPH) stake by 319% in Q1 2026, buying an estimated $495K and bringing the position to 44,448 shares worth $659K. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

Ameriprise first reported a position in AUPH in Q2 2017 and has held it in 19 quarters since. The position peaked at $2.98M in Q4 2019. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Ameriprise held 44,448 shares of Aurinia Pharmaceuticals worth $659K as of Q1 2026.
  • Ameriprise bought 33,845 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $495K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3475 holding.
  • Ameriprise first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 19 quarters since.
  • Ameriprise's Aurinia Pharmaceuticals position peaked at $2.98M in Q4 2019.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.